Abstract

The pathophysiology of tobacco-related diseases is complex and multifactorial. Among the various compounds in tobacco smoke are carcinogens such as nitrosamines, irritants such as a variety of phenolic compounds, volatiles such as carbon monoxide, and of course nicotine. Nicotine itself has quite complex actions, mediated in part by nicotinic cholinergic receptors that may have extraneuronal, as well as neuronal distribution. Its actions have also been implicated in a variety of neurodegenerative and psychiatric disorders. This short review discusses the recent pharmacology of nicotine and recent progress on its possible therapeutic benefits.

Introduction

There is little doubt that the majority of people who smoke tobacco do so in order to experience the psychopharmacological properties of nicotine present in smoke and that a significant proportion of habitual tobacco users become addicted to the drug.1 As a result, nicotine itself has been used increasingly by many smokers wanting to stop smoking highlighting its important therapeutic role. However, nicotine has also been found to influence neural systems in the brain that are thought to be involved in a range of neurological disorders. The rate of smoking is much higher in schizophrenics (up to 90%), depressed patients (up to 65%) and alcoholics (up to 90%) than in the general population.2 It appears that these effects of nicotine are mediated through selective activation of different subtypes of the neuronal nicotinic acetylcholine receptor (nAChR). Nicotine interacts with a variety of pre-synaptic nAChRs to facilitate the release of a number of neurotransmitters including acetylcholine (ACh), dopamine (DA), noradrenaline (NA), serotonin (5-HT), gamma-aminobutyric acid (GABA) and glutamate, many of which play an important role in mediating a number of cognitive functions.3 Recent studies on the effects of nicotinic receptor stimulation in neural dysfunction show the potential for therapeutic utility of nicotinic drugs.

Neuronal nicotinic receptors

Nicotinic receptors are cationic channels mediating fast synaptic transmission whose opening is controlled by ACh and nicotinic receptor agonists such as nicotine.4,5 They belong to a large family of homologous receptors including GABA<sub>α</sub>, glycine and the 5-HT<sub>1</sub> receptor.4 A number of different subtypes exist with individual pharmacological and physiological profiles and distinct anatomical distribution in the brain.6 To date, eight alpha (alpha2-7, 9, 10) and three beta (beta2 – beta4) nAChR subunits have been identified in mammals.8 By analogy with the muscle nAChRs, neuronal nAChRs are believed to have a pentameric structure consisting of five membrane spanning regions around a central ion channel. Although much is known about the structure and functional properties of neuronal nAChRs, relatively little is understood about their physiological role in man.9 Evidence suggests that nAChRs do not appear to function solely in the classical postsynaptic manner as their muscle counterparts as their location in the brain is not limited to postsynaptic but also to pre-, peri- and extrasynaptic sites.

Keywords

Nicotine, smoking, withdrawal, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, anxiety, psychiatric disorders

Charles Scerri PhD, CBiol MIBiol
Department of Clinical Pharmacology and Therapeutics
University of Malta, Msida, Malta
E-mail: charles.scerri@um.edu.mt
where they can modulate neuronal function by a variety of actions. These include a number of functional processes such as learning and memory, attention, cerebral blood flow and metabolism, as well as a growing list of pathological disorders including Alzheimer’s disease (AD) in which there is a significant loss of nAChR sites.

Nicotine withdrawal and reinforcement

Withdrawal from nicotine following smoking cessation results in symptoms such as depression, frustration, agitation, anxiety, difficulty of concentration and craving for tobacco. Although nicotine replacement therapies (NRTs) have been well established as smoking cessation aids following their ability to reverse the effects of nicotine withdrawal, some antidepressants such as fluoxetine and buproprion have also been reported to have beneficial effects on nicotine withdrawal symptoms. Moreover, buproprion appears to work equally well in smokers with and without past history of depression, suggesting that the efficacy of the drug is not due to its antidepressant effect. In behavioural studies using animal models, cessation of continuous nicotine infusions produces withdrawal symptoms similar to opiate withdrawal suggesting a possible common physiological mechanism.

Several behavioural studies have demonstrated the reinforcing properties of nicotine in animal models, which are also quite evident in humans. Nicotine can maintain self-administration behaviour in rats, and lesion and discrete microinjection studies have demonstrated a critical role for the mesolimbic DA pathways in nicotine self-administration. Mutant mice lacking the beta2 nAChR subunit do not self-administer nicotine denoting the possible involvement of functional beta2-containing nAChR subtypes in the rewarding effects of nicotine.

Nicotine and Parkinson’s disease

Parkinson’s disease (PD) is a progressive neurodegenerative condition involving the dopaminergic neurons of the substantia nigra. It is characterised by difficulty in initiating and smoothly sustaining movement. In PD there is loss of cholinergic cells in the basal forebrain accompanied by a significant reduction in the number of nicotine binding sites in the brain. The etiology of the disease is unknown, although it appears to be multifactorial in origin, possibly arising from a complex interaction between genetics and environment. The most commonly used treatment is dopamine replacement therapy. Although initially very effective, L-dopa provides only symptomatic relief with an inevitable disease progression. Moreover it loses efficacy with time and is accompanied by the development of drug-induced side effects.

The rationale for considering nicotine as a possible therapeutic agent is based on epidemiological findings that PD is less prevalent in smokers. Indeed this is the most robust observation linking environment and PD. Although cigarette smoking is composed of thousands of chemicals, nicotine represents a possible candidate for two reasons: it stimulates dopaminergic neurons that are selectively damaged in the striatum of PD patients and its exposure has been reported to protect against insults in various experimental models. Indeed, the inverse association between smoking and PD has been consistently reported in over 40 independent studies by different investigators over the past 50 years. Furthermore, the effects of smoking are dose dependent and related to the number of cigarette-pack-years. Although many questions remain unanswered, a recent study in twins demonstrating a reduced PD risk with smoking led the authors to conclude that there is a protective effect of cigarette smoking.

Nicotine and Alzheimer’s disease

Cholinergic transmitter replacement therapy forms the mainstay of Alzheimer’s disease (AD) symptomatic treatment and it is based on the hypothesis that low levels of ACh are responsible for the cognitive decline associated with the disease. Classically, replacement therapy has involved the use of cholinesterase inhibitors which prevent the breakdown of ACh at the cholinergic terminals, therefore increasing the concentration of the neurotransmitter available to interact with the receptors. It is also likely that the therapeutic benefit of cholinesterase inhibitor treatment occurs at least in part, through the activation of neuronal nAChRs either by direct action of the increased levels of ACh on these receptors or through allosteric modulation of the receptors. Neuronal nAChR activation is therefore currently being investigated as a strategy for AD therapy. The potential therapeutic benefit in AD from nAChR stimulation is based on three main observations. Firstly, stimulation of nAChR by nicotine or similar agonists improves memory function in animal models. Secondly, nAChR activation modulates the release of a number of neurotransmitters such as ACh, DA, GABA and glutamate which will enhance the release of ACh. Thirdly, there is evidence to suggest that nicotine provides protection against neurotoxic plaque formation, the concentrations of which are elevated in AD. Taking these observations, together with the reported loss of nAChR concentrations in AD, the development of nicotine-based therapies as potential therapeutic agents in AD should be promising. Indeed, clinical studies using nicotine dermal patches have reported a modest enhancement of cognitive performance in AD patients.

Nicotine and psychiatric disorders

Schizophrenia

Schizophrenia is a chronically deteriorating heterogeneous psychosis beginning in late adolescence or early adulthood and is characterised by hallucinations, delusions, bizarre behaviour, apathy and blunted affect. Previous epidemiological studies have shown that there is a high percentage of smokers present in the schizophrenic population (80 - 90%) compared with the general population (25 – 30%) and a low rate of smoking cessation among individuals with schizophrenia.
Schizophrenic patients have also been observed to have high levels of nAChR antibodies, which may be a contributing factor in the reduced number of nAChRs observed in schizophrenia. Smoking also decreases neuroleptic hepatic metabolism resulting in smokers needing a higher dose of antipsychotic therapy. While it is possible that smoking causes or exacerbates the condition, most studies suggest that the high incidence of smoking in schizophrenic patients is an attempt on their part to self-medicate nicotine to overcome a deficit in nicotinic neurotransmission. On a receptor level, post-mortem studies have shown a reduction in the number of alpha7-containing nAChRs in the hippocampus of schizophrenic patients compared to controls. Although further studies are needed to determine the neurophysiological mechanisms involved, these observations suggest that stimulation of this particular subunit by nicotinic agonists, such as nicotine, may be beneficial in schizophrenia.

**Anxiety and depression**

nAChRs are apparently involved in the pathophysiology of both anxiety disorders and depression. Nicotine administration has been observed to have anxiolytic effects in humans and in animal models of anxiety. This action may be blocked by antagonists to the nAChRs and by the benzodiazepine (BZ) channel blocker flumazenil suggesting that the anxiolytic action of nicotine may be the result of enhanced release of the inhibitory neurotransmitter GABA, which then acts on the central GABA_B-ZB multi-receptor complex.

Both retrospective and prospective clinical studies have demonstrated a relationship between smoking and major depression. The rate of smoking is much higher in depressed patients than in the general population. These patients have greater difficulty in stopping smoking and are at an increased risk of suffering mild to severe depression upon smoking cessation. Epidemiological studies have shown that the prevalence of depression in smokers is directly correlated with the prevalence of nicotine dependence, and smokers with a history of major depression are less likely to quit smoking. Moreover, smoking cessation frequently precipitates depressive symptoms that can be reversed by the reintroduction of smoking and evidence from clinical studies suggests that nicotine patches have antidepressant action. Therefore, it may appear that smoking is a self-medication effort intended to alleviate some symptoms of depression using nicotine. However, it is difficult to evaluate the antidepressant properties of nicotine in smokers because it is difficult to separate the antidepressant effect per se from the alleviation of depression that follows nicotine withdrawal.

There is also a considerable body of evidence linking the action of classical tricyclic antidepressants (TCAs) and the selective serotonin reuptake inhibitors (SSRIs) to nAChRs. The majority of TCAs, including imipramine, amitriptyline and nortriptyline, all produce a non-competitive inhibition of nAChRs. The SSRIs fluoxetine, paroxetine, sertaline and venlafaxine also produce similar reversible non-competitive inhibition of nAChRs. Furthermore, in rat hippocampal slices, fluoxetine has been found to inhibit nicotine-induced release of noradrenaline in a dose-dependent manner. Despite the well-characterised relationship between smoking, depression, antidepressants, and nicotine, the role of nicotine-sensitive receptors in the brain as targets for antidepressant treatment remains underappreciated.

**Conclusion**

Smoking has been shown to be associated with the occurrence of many fatal diseases and is currently the single most preventable cause of death. However, the possibility exists that nicotine may be beneficial in the protection against a number of diseases with relatively low frequencies. More studies are needed to clarify the various possible biological effects of tobacco smoking, particularly through its nicotine component in neurodegenerative and psychiatric disorders.

**References**


